STOCKS TELEGRAPH

Tag: Rockwell stock

  • Pre-Market Rally: Rockwell Medical (RMTI) Stock Shows Strong Uptrend

    Pre-Market Rally: Rockwell Medical (RMTI) Stock Shows Strong Uptrend

    The news of a multi-year sales deal has caused shares of Rockwell Medical, Inc. (NASDAQ: RMTI) to jump noticeably on the charts. The pre-market session as of the last check, saw RMTI shares rise 16.92% to $2.35. Investor confidence in the company’s strategic efforts and market presence is reflected in this upswing.

    Important Deal with World Dialysis Leader

    Rockwell Medical has inked a deal to sell items to a major worldwide supplier of dialysis supplies and services. Being the leading supplier of liquid bicarbonate in the US, Rockwell Medical is in a unique position since no other company can produce liquid bicarbonate on a large enough scale to satisfy the needs of the country’s largest dialysis providers.

    For a three-year initial agreement, with the possibility of two one-year extensions, RMTI will provide its SteriLyte liquid bicarbonate hemodialysis concentrates. Over $10 million in net sales are predicted in the first year of the arrangement, with more price hikes likely in the following years.A portion of this revenue was not included in previously disclosed estimates for 2025, indicating additional growth potential.

    Partnership with HydroCare Expands Product Reach

    In a separate development, RMTI has partnered with HydroCare, a global leader in dialysis water treatment systems. This collaboration focuses on installing Rockwell Medical’s DAMX45 dry acid concentrate mix system in dialysis water rooms. The system, which is FDA 510(k)-approved, works seamlessly with the company’s CitraPure and Dri-Sate dry acid concentrates.

    The DAMX45 mixer enables clinics to prepare 100 gallons of acid concentrate on-site in just three minutes, significantly improving efficiency. HydroCare recognized the system’s reliability and ease of use, making it an ideal choice for enhancing dialysis water room operations. This partnership provides Rockwell Medical with a pathway to extend its market reach and benefit more patients globally.

    A Commitment to Advancing Dialysis Care

    These tactical partnerships highlight Rockwell Medical’s commitment to providing cutting-edge solutions that enhance patient care. RMTI is ideally positioned for long-term growth in the dialysis industry because to its robust market presence and cutting-edge product offerings.

  • Market Drove Rockwell Medical (RMTI) Stock Up For Third Consecutive Day

    Market Drove Rockwell Medical (RMTI) Stock Up For Third Consecutive Day

    Rockwell Medical, Inc. (NASDAQ: RMTI) experienced a remarkable rally this week, with its stock price surging for three consecutive days. On Wednesday, RMTI shares jumped by 8.18%, closing at $4.10, a significant leap attributed to a major product purchase order win. The primary catalyst for this increase is a significant purchase order that has propelled investor confidence.

    Rockwell Medical Inked Major Product Purchase Agreement

    This week, a significant product purchase agreement between Rockwell Medical and a well-known US provider of acute care and at-home dialysis services was revealed. The deal states that Rockwell Medical will deliver its RenalPure liquid acid and SteriLyte liquid bicarbonate solutions to this top healthcare provider.

    These hemodialysis concentrates will be delivered in two distinct packaging options: a four-per-case packaging for larger dialysis centers and a two-per-case packaging designed for smaller acute care settings and at-home treatments.

    Advantages of RMTI’s Hemodialysis Convenience Pack

    The convenience pack offered by Rockwell Medical includes two 1-gallon pre-mixed containers of RenalPure or SteriLyte, providing several benefits to patients, caregivers, and healthcare providers. This creative packaging is particularly helpful for home patients and acute care centers since it streamlines handling and increases workflow efficiency.

    With the increasing demand for cutting-edge dialysis technologies, especially in the underserved at-home hemodialysis market, Rockwell Medical’s products present a worthwhile substitute for conventional in-clinic treatments that frequently necessitate patients to make lengthy weekly travels.

    Strategic Alliance with Nipro Medical

    In a related development, Rockwell Medical and Nipro Medical Corporation, two global leaders in the healthcare and medical device sectors, have entered into a distribution agreement. A division of Nipro Corporation Japan is Nipro Medical Corporation.

    Nipro will receive its liquid, dry, and bicarbonate hemodialysis concentrates from Rockwell Medical in accordance with the conditions of this agreement, as well as its dry acid concentrate mixer. The rights to distribute these items internationally—apart from the US—have been licensed to Nipro.

    This two-year deal contains a minimum purchase requirement of $5.0 million for the first year, with progressive increases in succeeding years, and an option for a one-year extension. The increased demand for Rockwell Medical’s hemodialysis product range in the market is in line with Nipro’s reputation for producing high-quality medical equipment, especially in the renal and cardiovascular sectors.

  • Pre-Market Cues: 30 Stocks Roaring for Change On December 14th

    Sonoma Pharmaceuticals Inc. (SNOA) stock plunged -7.53% to $8.1 in the pre-market trading after reporting partnership with Crown Laboratories to launch Microcyn® technology-based anti-itch over-the-counter products.

    Livent Corporation (NYSE: LTHM) shares are trading up 3.6% at $17.0 at the time of writing. Company’s 52-week ranged between $3.95 to $17.53. Analysts have a consensus price target of $16.50.

    Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares are trading down -5.45% at $2.95 at the time of writing after declaring offering of common stock. Company’s 52-week ranged between $1.03 to $5.31.

    NextDecade Corporation (NEXT) is down more than -7.25% at $3.2 in pre-market hours Monday December 14, 2020. The stock had jumped over 38.00% to $3.45 in the last trading session.

    FAT Brands Inc. (FAT) tumbled over -4.06% at $7.57 in pre-market trading today following the announcement from the company that it has entered into an agreement to combine with Fog Cutter Capital Group Inc. (FCCG), the Company’s controlling stockholder.

    Recro Pharma Inc. (REPH) stock soared 3.21% to $3.05 in the pre-market trading. The most recent rating by Stephens, on October 17, 2019, is an Overweight.

    Ampio Pharmaceuticals Inc. (AMPE) stock moved up 3.33 percent to $1.55 in the pre-market trading.

    ReTo Eco-Solutions Inc. (RETO), a Building Materials company, rose about 3.91% at $0.665 in pre-market trading Monday.

    Yiren Digital Ltd. (YRD) lost over -5.36% at $3.0 in pre-market trading Monday December 14, 2020. The firm recently announced that it has entered into two collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion™.

    Before the trading started on December 14, 2020, Sabre Corporation (SABR) is up 3.46% to reach $11.35. It has been trading in a 52-week range of $3.30 to $23.25.

    NantHealth Inc. (NH) is up more than 1.74% at $3.5 in pre-market hours Monday December 14, 2020. The company recently presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS) new significant findings around the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer and the potential clinical and cost benefits of biosimilars. The stock had jumped over 22.42% to $3.44 in the last trading session.

    Torchlight Energy Resources Inc. (TRCH) stock soared 15.79% to $0.88 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.

    NIO Limited (NYSE: NIO) shares are trading down -6.38% at $39.3 at the time of writing following the announcement of pricing of offering of 68,000,000 American Depositary Shares. Company’s 52-week ranged between $2.11 to $57.20. Analysts have a consensus price target of $59.

    Lightbridge Corporation (LTBR) is down more than -2.4% at $3.66 in pre-market hours Monday December 14, 2020. The stock had jumped over 12.28% to $3.75 in the last trading session.

    Foresight Autonomous Holdings Ltd. (FRSX) stock moved up 2.31 percent to $1.77 in the pre-market trading after its affiliate, Rail Vision Ltd., has received an order from Knorr-Bremse Systeme für Schienenfahrzeuge GmbH, an affiliate of Knorr-Bremse AG (Frankfurt: KBX), for two samples of their light rail vehicle (LRV) system.

    Before the trading started on December 14, 2020, Hennessy Capital Acquisition Corp. IV (HCAC) is up 2.32% to reach $20.75. It has been trading in a 52-week range of $9.21 to $22.43.

    Inseego Corp. (INSG) stock soared 10.36% to $15.18 in the pre-market trading after reporting that the company is expanding its global footprint in Japan with the launch of its industry-leading 5G MiFi® M2000 mobile hotspot. The most recent rating by ROTH Capital, on August 06, 2020, is a Neutral.

    Mechel PAO (MTL) is down more than -3.66% at $1.84 in pre-market hours Monday December 14, 2020. The stock had jumped over 11.05% to $1.91 in the last trading session.

    JinkoSolar Holding Co. Ltd. (NYSE: JKS) shares are trading up 3.58% at $54.9 at the time of writing after declaring an update to 2020 annual general meeting agenda. Company’s 52-week ranged between $11.42 to $90.20. Analysts have a consensus price target of $55.

    Before the trading started on December 14, 2020, CureVac N.V. (CVAC) is up 6.7% to reach $125.99. It has been trading in a 52-week range of $36.15 to $151.80.

    Xeris Pharmaceuticals Inc. (XERS) grew over 2.84% at $4.7 in pre-market trading today after recent proclamation from company that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive Opinion for Ogluo™ (glucagon).

    Teligent Inc. (NASDAQ: TLGT) shares are trading up 85.54% at $1.17 at the time of writing. Company’s 52-week ranged between $0.46 to $6.46. Analysts have a consensus price target of $2.

    Marathon Patent Group Inc. (MARA) gained over 15.58% at $5.49 in pre-market trading Monday December 14, 2020. The firm recently announced a contract with Bitmain to purchase 10,000 Antminer S-19j Pro ASIC Miners.

    Sundial Growers Inc. (NASDAQ: SNDL) shares are trading up 4.64% at $0.53 at the time of writing after reporting that it has received approval to transfer the listing of its common shares to the Nasdaq Capital Market. Company’s 52-week ranged between $0.14 to $3.88.

    Neos Therapeutics Inc. (NEOS) tumbled over -5.61% at $0.6532 in pre-market trading today. The company and Aytu BioScience, Inc. (AYTU) recently declared that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.

    Arbutus Biopharma Corporation (ABUS), a Biotechnology company, rose about 6.14% at $4.15 in pre-market trading Monday. The healthcare firm lately declared additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.

    Greenwich LifeSciences Inc. (GLSI) lost over -16.07% at $47.0 in pre-market trading Monday December 14, 2020 following the publication of a second poster for the GP2 Phase III clinical trial design for recurring breast cancer at the San Antonio Breast Cancer Symposium (SABCS) in a virtual format.

    Veru Inc. (VERU) is up more than 19.12% at $7.57 in pre-market hours Monday December 14, 2020 following the company revealed positive Phase 2 clinical trial results for enobosarm, for the treatment of endocrine and chemotherapy resistant ER+/HER2- metastatic breast cancer. The stock had jumped over 6.45% to $6.36 in the last trading session.

    NanoVibronix Inc. (NAOV) stock plunged -6.36% to $1.03 in the pre-market trading after reporting that it has expanded and replaced its original distribution agreement with Ultra Pain Products, Inc..

    SELLAS Life Sciences Group Inc. (NASDAQ: SLS) shares are trading down -11.23% at $7.43 at the time of writing following the pricing of $16.2 million registered direct offering. Company’s 52-week ranged between $1.46 to $19.38.